Literature DB >> 17401172

Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.

Maria A Thomas1, Jacqueline F Spencer, William S M Wold.   

Abstract

Oncolytic adenoviruses (Ads) are promising candidates for cancer therapy. However, current animal models to evaluate these vectors have substantial limitations. Because Ad replication is generally species-specific, oncolytic Ads are usually examined in immunodeficient mice bearing human xenograft tumors. However, this model suffers because the animals are immunodeficient and normal and cancerous mouse tissues are poorly permissive to human Ad replication. We have recently developed a Syrian hamster model that is both immunocompetent and permissive to human Ad replication in normal and cancerous tissues. The Syrian hamster is also permissive for Ad5 replication in the lung, which is the natural site of infection in humans. Human Ads replicate well in vitro in the Syrian hamster cell lines examined and demonstrate significant antitumor efficacy following injection into Syrian hamster tumors in vivo. In this chapter we describe the maintenance of these Syrian hamster cell lines in culture and how to assess oncolytic Ad vector replication in these cells in vitro. We also describe detailed methods for growth of these cell lines as subcutaneous tumors, for intravenous and intratumoral injections in hamsters, and for evaluation of the efficacy, replication, and biodistribution of oncolytic Ad vectors following administration in hamsters. In addition, we describe how to assess replication in normal tissues such as the lungs and give helpful tips on handling, anesthesia, and general care of Syrian hamsters.

Entities:  

Mesh:

Year:  2007        PMID: 17401172     DOI: 10.1385/1-59745-166-5:169

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  32 in total

Review 1.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

2.  Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer.

Authors:  Reeti Khare; Shannon M May; Francesco Vetrini; Eric A Weaver; Donna Palmer; Amanda Rosewell; Nathan Grove; Philip Ng; Michael A Barry
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

3.  Mucosal vaccination by adenoviruses displaying reovirus sigma 1.

Authors:  Eric A Weaver; Zenaido T Camacho; Matthew L Hillestad; Catherine M Crosby; Mallory A Turner; Adam J Guenzel; Hind J Fadel; George T Mercier; Michael A Barry
Journal:  Virology       Date:  2015-03-30       Impact factor: 3.616

4.  Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex.

Authors:  Rong Li; Jinxin Miao; Zhiqiang Fan; SeokHwan Song; Il-Keun Kong; Yaohe Wang; Zhongde Wang
Journal:  J Vis Exp       Date:  2018-01-09       Impact factor: 1.355

5.  A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.

Authors:  Stephanie S Anguiano-Zarate; William E Matchett; Pramod N Nehete; Jagannadha K Sastry; Andrea Marzi; Michael A Barry
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

6.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

Authors:  Maria A Thomas; Jacqueline F Spencer; Karoly Toth; John E Sagartz; Nancy J Phillips; William S M Wold
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

8.  Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

9.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

10.  IIIa deleted adenovirus as a single-cycle genome replicating vector.

Authors:  Catherine M Crosby; Michael A Barry
Journal:  Virology       Date:  2014-07-02       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.